Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials

References

• Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48(11):2485–2492.
   PubMed Web of Science ®Google Scholar
• Koga K, Matsuno Y, Noguchi M, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44(5):359–367.
   PubMed Web of Science ®Google Scholar
• Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5:S260–5.
   PubMed Web of Science ®Google Scholar
• Strobel P, Hohenberger P, Marx A. Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol. 2010;5:S286–90.
   PubMed Web of Science ®Google Scholar
• Marx A, Ströbel P, Badve SS, et al. ITMIG consensus statement on the use of theWHO histological classification of thymoma and thymic carcinoma refined definitions, histological criteria, and reporting. J Thorac Oncol. 2014;9:596–611.
   PubMed Web of Science ®Google Scholar
• Den Bakker MA, Roden AC, Marx A, et al. Histologic classification of thymoma: a practical guide for routine cases. J Thorac Oncol. 2014;9:S125–30.
   PubMed Web of Science ®Google Scholar
• Chalabreysse L, Roy P, Cordier J-F, et al. Correlation of the WHO schema for the classification of thymic epithelial neoplasms with prognosis: a retrospective study of 90 tumors. Am J Surg Pathol. 2002;26(12):1605–1611.
   PubMed Web of Science ®Google Scholar
• Weis CA, Yao X, Deng Y, et al. The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol. 2015;10(2):367–372.
   PubMed Web of Science ®Google Scholar
• Roden AC, Yi ES, Jenkins SM, et al. Modified Masaoka stage and size are independent prognostic predictors in thymoma and modified Masaoka stage is superior to histopathologic classifications. J Thorac Oncol. 2015;10(4):691–700.
   PubMed Web of Science ®Google Scholar
• Conforti F, Marino M, Vitolo V, et al. Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM). ESMO Open. 2021;6(4):100188.
   PubMed Web of Science ®Google Scholar
• Radovich M, Pickering CR, Felau I, et al. The integrated genomic Landscape of thymic epithelial tumors. Cancer Cell. 2018;33:244–258.
   PubMed Web of Science ®Google Scholar
• Wang Y, Thomas A, Lau C, et al. Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep. 2014;4:7336.
   PubMed Web of Science ®Google Scholar
• Petrini I, Wang Y, Zucali PA, et al. Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. Clin Cancer Res. 2013;19:1960–1971.
   PubMed Web of Science ®Google Scholar
• Padda SK, Riess JW, Schwartz EJ, et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015;10:500–508.
   PubMed Web of Science ®Google Scholar
• Tomita M, Matsuzaki Y, Edagawa M, et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg. 2002;124:493–498.
   PubMed Web of Science ®Google Scholar
• Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16:177–186.
   PubMed Web of Science ®Google Scholar
• Sato J, Satouchi M, Itoh S, et al. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol. 2020;21(6):843–850.
   PubMed Web of Science ®Google Scholar
• Perrino M, De Pas T, Bozzarelli S, et al. Resound Trial: a phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy. Cancer. 2022;128(4):719–726.
   PubMed Web of Science ®Google Scholar
• Hussein Z, Mizuo H, Hayato S, et al. Clinical Pharmacokinetic and Pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted Tyrosine Kinase inhibitor. Eur J Drug Metab Pharmacokinet. 2017;42:903–914.
   PubMed Web of Science ®Google Scholar
• Dudeck O, Zeile M, Reichardt P, et al. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2011;22(8):1828–1833.
   PubMed Web of Science ®Google Scholar
• Remon J, Girard N, Mazieres J, et al. Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network. Lung Cancer. 2016;97:99–104.
   PubMed Web of Science ®Google Scholar
• Imbimbo M, Vitali M, Fabbri A, et al. RELEVENT trial: phase II trial of ramucirumab, carboplatin, and paclitaxel in previously untreated thymic carcinoma/B3 thymoma with area of carcinoma. Clin Lung Cancer. 2018;19:e811–4.
   PubMed Web of Science ®Google Scholar
• Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170:1257–1266.
   PubMed Web of Science ®Google Scholar
• Repetto M, Conforti F, Pirola S, et al. Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. Eur J Cancer. 2021;153:162–167.
   PubMed Web of Science ®Google Scholar
• Machens A, Loliger C, Pichlmeier U, et al. Correlation of thymic pathology with HLA in myasthenia gravis. Clin Immunol. 1999;91:296–301.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma:a single-arm,single-centre,phase 2 study. Lancet Oncol. 2018;19:347–355.
   PubMed Web of Science ®Google Scholar
• Cho J, Kim HS, Ku BM, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2018. DOI:10.1200/JCO.2017.77.3184.
   Google Scholar
• Katsuya Y, Horinouchi H, Seto T, et al. Single arm multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. EJC. 2019;113:78–86.
   Google Scholar
• Girard N, Ponce Aix S, Cedres S, et al. LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. Ann Oncol. 2021;32:S1342.
   Google Scholar
• He Y, Ramesh A, Gusev Y, et al. Molecular predictors of response to pembrolizumab in thymic carcinoma. Cell Rep Med. 2021; 2: 100392.
   PubMedGoogle Scholar
• Rajan A, Heery CR, Thomas A. Thomas A, et al.Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer. 2019;7:269.
   PubMed Web of Science ®Google Scholar
• Arance Fernandez AM, O’Day SJ, de la Cruz Merino L, et al. Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004. ESMO Virtual Congress 2020: Abstract LBA44. Presented. 2020 Sep 19.
   Google Scholar
• Motzer R, Choueiri TK. Lenvatinib plus pembrolizumab for renal cell carcinoma reply. N Engl J Med. 2021;385:287.
   PubMed Web of Science ®Google Scholar
• Brose M, Vogelzang NJ, DiSimone C, et al. A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer. J Clin Oncol. 2019;37:16.
   Google Scholar
• Conforti F, Pala L, Catania C, et al. Safety and activity of combined AVElumab with axitinib in unresectable or metastatic thymomas B3 and thymic carcinomas: the CAVEATT study. J clin oncol. 2020;38(15_suppl):e21114–e21114.
   Web of Science ®Google Scholar
• Remon J, Girard N, Novello S, et al. PECATI: a multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated b3-thymoma and thymic carcinoma patients. Clin Lung Cancer. 2021;00189-3(21):S1525–7304.
   Google Scholar
• Berezhnoy A, Sumrow BJ, Stahl K, et al. Development and preliminary clinical activity of PD-1-guided CTLA-4 blocking bispecific DART molecule. Cell Rep Med. 2020;1(9):100163.
   PubMedGoogle Scholar
• Burton EM, Tawbi HA. Bispecific antibodies to PD-1 and CTLA4: doubling down on T cells to decouple efficacy from toxicity. Cancer Discov. 2021;11(5):1008–1010.
   PubMed Web of Science ®Google Scholar
• Strauss J, Gatti-Mays ME, Cho BC, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer. 2020;8(2):e001395.
   PubMed Web of Science ®Google Scholar
• Isvoranu G, Surcel M, Munteanu AN, et al. Therapeutic potential of interleukin-15 in cancer (Review). Exp Ther Med. 2021;22(1):67.
   Web of Science ®Google Scholar
• Petrini I, Wang Y, Zucali PA, et al. Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. Clin Cancer Res. 2013;19:1960–1971.
   PubMed Web of Science ®Google Scholar
• Petrini I, Meltzer PS, Zucali PA, et al. Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis. 2012 19;3:e351.
   PubMed Web of Science ®Google Scholar
• Besse B, Garassino MC, Rajan A, et al. Efficacy of Milciclib (PHA-848125AC), a pan cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients. J Clin Oncol. 2018;36(15_suppl):8519.
   Web of Science ®Google Scholar
• Alberobello AT, Wang Y, Beerkens FJ, et al. PI3K as a potential therapeutic target in thymic epithelial tumors. J Thorac Oncol. 2016;11:1345–1356.
   PubMed Web of Science ®Google Scholar
• Palmieri G, Buonerba C, Federico P, et al. Everolimus plus long acting somatostatin analogs in thymic epithelial malignancies. World J Clin Oncol. 2012;2:111–115.
   Google Scholar
• Zucali PA, De Pas T, Palmieri G, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol. 2018;36:342–349.
   PubMed Web of Science ®Google Scholar
• Abu Zaid MI, Radovich M, Althouse SK, et al. A phase II study of BKM120 (buparlisib) in relapsed or refractory thymomas. J Clin Oncol. 2018;36(15_suppl):e20580–e20580.
   Google Scholar
• Conforti F, Wang Y, Rodriguez JA, et al. Molecular pathways: anticancer activity by inhibition of nucleocytoplasmic shuttling. Clin Cancer Res. 2015;21:4508–4513.
   PubMed Web of Science ®Google Scholar
• Conforti F, Zhang X, Rao G, et al. Therapeutic effects of XPO1 inhibition in thymic epithelial tumors. Cancer Res. 2017;77(20):5614–5627.
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1:e000023.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Yang WI, Kim SH, et al. Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. Eur J Cardiothorac Surg. 2005;28:611–616.
   PubMed Web of Science ®Google Scholar
• Salame H, Mckey R, Ballout M, et al. The first reported case of neurotrophic tyrosine receptor Kinase fusion-positive thymoma treated successfully with entrectinib. Cureus. 2021;13:e20588.
   PubMed Web of Science ®Google Scholar
• Chung V, Wang L, Fletcher MS, et al. First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma. J Clin Oncol. 2021;39(15_suppl):3081–308.
   Web of Science ®Google Scholar
• Conforti F, Pala L, Giaccone G, et al. Thymic epithelial tumors: from biology to treatment. Cancer Treat Rev. 2020;86:102014.
   PubMed Web of Science ®Google Scholar
• Kalev P, Hyer ML, Gross S, et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. Cancer Cell. 2021;39:209–224.e11.
   PubMed Web of Science ®Google Scholar
• Jing W, Zhu H, Liu W, et al. MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab. Sci Rep. 2020;10:843.
   PubMed Web of Science ®Google Scholar
• Gbolahan OB, Porter RF, Salter JT, et al. A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma. J Thorac Oncol. 2018;13:1940–1948.
   PubMed Web of Science ®Google Scholar
• Smith C, Engstrom L, Kulyk S, et al. MRTX1719: a first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models. Mol Cancer Ther. 2021;20 (12_Supplement):P165. DOI: 10.1158/1535-7163.TARG-21-P165.
   Google Scholar
• National Comprehensive Cancer Network. National Comprehensive Cancer Network. Thymomas and thymic cancers (Version 1.2022). cited 2022 Feb 1, Available from http://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf
   Google Scholar
• Petrini I, Meltzer PS, Kim IK, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet. 2014 Aug;46:844–849.
   PubMed Web of Science ®Google Scholar
• Blay JY, Casali P, Bouvier C, et al. European reference network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN. ESMO Open. 2021;6:100174.
   PubMed Web of Science ®Google Scholar
• Imbimbo M, Ottaviano M, Vitali M, et al. Best practices for the management of thymic epithelial tumors: a position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). Cancer Treat Rev. 2018;71:76–87.
   PubMed Web of Science ®Google Scholar